Timing of Resumption of Direct Oral Anticoagulants Following Polypectomy
Timing of Resumption of Direct Oral Anticoagulants Following Colonoscopy Polypectomy: a Prospective Randomized Non-inferiority Trial
The University of Hong Kong
194 participants
Oct 3, 2024
INTERVENTIONAL
Conditions
Summary
The goal of this prospective randomized non-inferiority trial is to compare two different resumption time of Direct Oral Anticoagulants (DOACs) after colonoscopic polypectomy. We hypothesize that early resumption of DOACs after colonoscopy and polypectomy is associated with comparable post-polypectomy bleeding rate to those with delayed resumption. This study aims to compare the post-polypectomy bleeding risk of two different timing of resuming DOACs (Day 0 vs Day 2):
Eligibility
Inclusion Criteria1
- \- All adult patients who are taking DOACs and schedule for elective colonoscopy are potentially eligible. We only included patients who had complete colonoscopy and with polypectomy performed.
Exclusion Criteria6
- Previous resection of any colonic segments,
- Inflammatory bowel disease or polyposis syndrome
- Patient with large polyp required advanced procedure e.g. endoscopic submucosal dissection (ESD) to remove
- Patients who develop immediate post-polypectomy bleeding during the procedure and requiring haemostasis will also be excluded
- Patient without polypectomy
- Patient without complete colonoscopy done
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Time for resumption of DOAC
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06482333